Vaccine Production

The technology of mammary gland bioreactors is revolutionizing vaccine production by harnessing the innate protein synthesis capabilities of mammary glands. Through the integration of vaccine antigen genes into the genome of host animals, this method facilitates large-scale production of recombinant proteins that are subsequently secreted in milk. The utilization of mammary gland bioreactor systems has emerged as a promising and cost-effective alternative for scalable vaccine production against infectious diseases and cancers.

Types of Vaccines

Different types of vaccines can be effectively produced using mammary gland bioreactor technology, each designed to trigger specific immune responses for disease prevention. Below are the major vaccine types that benefit from this platform.

Protein Subunit Vaccines

Subunit vaccines use only a part of the pathogen (such as a protein or polysaccharide) to stimulate the immune system. Mammary gland bioreactors are well-suited for producing the antigens needed for these vaccines because they allow the production of specific protein subunits in high quantities. Subunit vaccines, such as those for influenza and pertussis, could potentially benefit from this technology.

Conjugate Vaccines

Conjugate vaccines combine a weak antigen with a strong antigen to elicit a stronger immune response. Mammary gland bioreactors can help produce the protein components of these vaccines, especially those targeting diseases like Haemophilus influenzae type B (Hib).

Therapeutic Cancer Vaccines

Therapeutic cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. Mammary gland bioreactors can be used to produce tumor-associated antigens (TAAs) or neoantigens, which are key components in these vaccines. This platform enables high-yield production of personalized vaccine components for immunotherapy approaches targeting cancers such as bladder cancer, melanoma, and prostate cancer.

Workflow of Vaccine Production Using Mammary Gland Bioreactors

The vaccine production process through mammary gland bioreactors involves several critical steps, each designed to maximize yield and ensure the quality of the final vaccine product. The key stages are outlined below.

Gene Editing and Vector Design

Utilizing advanced CRISPR/Cas9, TALENs and Cre-loxP technologies to optimize gene integration and expression.

Milk-based Antigen Extraction

Efficient extraction and purification of antigens from mammary gland secretions for downstream vaccine formulation.

Antigen Production Optimization

Enhancing antigen yield through targeted regulatory sequence improvement and site-specific gene integration.

Vaccine Formulation and Testing

Comprehensive support for the formulation, stability testing, and preclinical evaluation of vaccine candidates.

Welcome to consult for details, CD BioSciences will develop a detailed service agreement according to your program and needs. For more experimental technology services, please browse the rest of our website or contact us.

Our services are for research use only and cannot be used for any clinical purposes.